A LIFE-SAVING STORY: WHAT IT REVEALS ABOUT HEALTH INSURANCE AND THE WELL-BEING OF PEOPLE IN CHINA AND THE UNITED STATES
This life-saving story is directly connected to how China and the United States approach health insurance and the well-being of their people.
By Johnson Choi, MBA
International Business and Financial Consultant since 1985
這個救命的故事和中美二國如果對待醫療保險和人民的福祉有直接關係. 以一位六十歲的男士為例, 美國醫保每月是US$1,200, 中國是每月US$8.
作者: 蔡永強，商科碩士，國際財經顧問，1985年至今.
一個名叫MaxDoppelt的美國小哥，千里迢迢，跨越半個地球，飛到上海，購買了一批在美國都還沒有上市的新葯，只為拯救自己的母親！
美國《華盛頓郵報》中文標題：美國癌症患者急需救命藥物，部分人不得不前往中國取得。刊登日期：2026年10月20日
作者：Arthur Allen
原始新聞機構：KFF Health News
轉載媒體：The Washington Post
這款中國抗癌藥已獲美國 FDA 批准
舒沃替尼（Sunvozertinib）
商品名稱：Zegfrovy
研發企業：中國迪哲醫藥（Dizal Pharmaceutical）
中國批准：2023年
美國 FDA 批准：2025年7月2日. 美國商業供應：2026年10月報道時仍未普遍上市，藥廠正在推進供應。👉但還需要保險公司批準. 價錢可能是中國的好幾倍!👈
美國 FDA 的臨床試驗資料顯示，這款藥物針對帶有特定 EGFR exon 20 插入突變的晚期非小細胞肺癌患者，在主要療效分析的85名患者中，腫瘤客觀緩解率為46%。這不是所有肺癌患者的治癒率。
另外，根據2026年10月23日香港《南華早報》的跟進報道，阿斯利康（AstraZeneca）正推進該藥在美國的商業銷售。
Take a 60-year-old man as an example: Health insurance in the United States costs US$1,200 per month, compared with just US$8 per month in China.
An American man named Max Doppelt traveled halfway around the world to Shanghai, China, to purchase a supply of newly developed medication that was not yet commercially available in the United States—all in a desperate effort to save his mother’s life!
THE WASHINGTON POST REPORT
Headline: U.S. Cancer Patients Need Lifesaving Drugs. Some Have to Get Them in China.
- Publication date: October 20, 2026
- Author: Arthur Allen
- Original news organization: KFF Health News
- Republished by: The Washington Post
CHINA-DEVELOPED CANCER DRUG ALREADY APPROVED BY THE U.S. FDA
Drug name: Sunvozertinib (舒沃替尼)
Brand name: Zegfrovy
Developer: Dizal Pharmaceutical, China
Approved in China: 2023
U.S. FDA approval: July 2, 2025
Commercial availability in the United States: As of the October 2026 report, the medication was still not widely available commercially in the United States, and the pharmaceutical company was working to establish its commercial supply.
👉 However, patients may still need approval from their health insurance companies before the treatment is covered. The price in the United States could potentially be several times higher than in China! 👈
CLINICAL TRIAL RESULTS: A SIGNIFICANT ADVANCE IN CANCER TREATMENT
According to clinical trial data reviewed by the U.S. Food and Drug Administration (FDA), Sunvozertinib is designed to treat patients with advanced non-small cell lung cancer carrying specific EGFR exon 20 insertion mutations.
Among 85 patients included in the primary efficacy analysis, the objective tumor response rate was 46%.
This means that approximately 46% of these patients experienced a measurable reduction in their tumors. It does not mean that 46% of all lung cancer patients were cured.
Furthermore, according to a follow-up report published by Hong Kong’s South China Morning Post on October 23, 2026, AstraZeneca was moving forward with the commercial distribution of this China-developed cancer drug in the United States.
This life-saving story raises an important question:
Shouldn’t affordable access to life-saving medicines and the health and well-being of ordinary people be among the highest priorities of every healthcare system?
